Short report: Bronchoconstriction following nebulised colistin in cystic fibrosis
Open Access
- 1 May 2001
- journal article
- general and-acute-paediatrics
- Published by BMJ in Archives of Disease in Childhood
- Vol. 84 (5) , 432-433
- https://doi.org/10.1136/adc.84.5.432
Abstract
Nebulised colistin is regularly used as antipseudomonal therapy in children with cystic fibrosis. We assessed bronchoconstriction in response to nebulised colistin in 58 children. Nebulised colistin significantly reduced FEV1, MEF25%, and Sao 2 for 15 minutes. In 20 children the reduction was greater than 10% from baseline FEV1, and was still at that level in five at 30 minutes. Subjective assessment, baseline FEV1, and serum IgE were unable to identify susceptible children. It is recommended that children receiving colistin should be carefully assessed for bronchoconstriction.Keywords
This publication has 6 references indexed in Scilit:
- Inhaled tobramycin and bronchial hyperactivity in cystic fibrosisPediatric Pulmonology, 2000
- Intermittent Administration of Inhaled Tobramycin in Patients with Cystic FibrosisNew England Journal of Medicine, 1999
- Effect of tonicity of nebulised colistin on chest tightness and pulmonary function in adults with cystic fibrosisThorax, 1997
- Nebulised antipseudomonal antibiotic therapy in cystic fibrosis: a meta-analysis of benefits and risks.Thorax, 1996
- Bronchial response to nebulized antibiotics in children with cystic fibrosisEuropean Respiratory Journal, 1990
- The functional development of the respiratory system from the period of gestation to adulthood.Published by Elsevier ,1979